Background: A cluster of aortic bioprosthetic valve failures, most of which were Trifecta bioprostheses, was observed in Southampton General Hospital, Southampton, United Kingdom. This study was performed to assess whether the cluster represents a significant failure of this valve model or whether there is a selection bias that can explain the failure of these valves.
Methods: This retrospective study evaluated all bioprosthetic aortic valve replacement operations performed between 2011 and 2016 inclusive in our center. The study compared the performance of the Trifecta valve (Abbott, Abbott Park, IL) with that of Perimount (Edwards Lifesciences, Irvine, CA), Perimount Magna Ease, and Mitroflow (LivaNova, London, United Kingdom) bioprostheses. In addition, the study analyzed patient-related and valve-related risk factors for early failure in the failed valves.
Results: A total of 2807 bioprosthetic aortic valve replacements were performed. Of these, 836 were Trifecta valves, 1031 were Perimount, 449 were Perimount Magna Ease, and 351 were Mitroflow valves. A total of 24 Trifecta valves had premature structural failure, a number significantly higher than seen with Perimount or Perimount Magna Ease (no failure, P < .001 and P < .005, respectively) valves and the Mitroflow valve (1 failure, P < .05). There was no difference in the incidence of endocarditis or death. At the time of valve failure, 17 (71%) of the failed Trifecta valves had moderate or severe regurgitation, and the average peak gradient was 61 ± 29 mm Hg. The median failed prosthetic size was 23 mm. One failed valve had severe patient-prosthesis mismatch. The mean time to failure was 4.5 ± 1.7 years.
Conclusions: The Trifecta bioprosthesis has an increased incidence of early structural valve failure, which is significantly higher than that of Perimount, Perimount Magna Ease, or Mitroflow. No patient-related or valve-related cause for the failure could be identified.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.athoracsur.2020.11.026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Balloon-assisted bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction with en face view for patients exhibiting severe calcified leaflet: a case report.
Eur Heart J Case Rep
December 2024
Department of Cardiology, Sendai Kousei Hospital, 1-20, Tsutsumidori Amamiya-cho, Aoba-ku, Sendai, Miyagi 981-0914, Japan.
Background: Balloon-assisted bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction (BA-BASILICA) enables valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) in patients at risk of coronary artery obstruction. However, its efficacy in patients with severely calcified leaflets remains unclear.
Case Summary: We report a 78-year-old woman with a deteriorated 21 mm Carpentier-Edwards PERIMOUNT Magna valve.
Sutureless and Rapid Deployment Prosthesis in Redo-Bentall Endocarditis.
Case Rep Surg
October 2024
Department of Cardiac Surgery, "Vito Fazzi" Hospital, Lecce, Italy.
Aortic valve replacement (AVR) in a patient with a bio-Bentall conduit can be very challenging, especially if there was a previous endocarditis process for significant morbidity and mortality. We report a case of sutureless AVR in an old patient with a bio-Bentall conduit (Carpentier-Edwards Perimount Magna Ease 25 aortic valve and Hemashield 30 aortic conduit), who developed an endocarditis on aortic prosthesis valve. We believe that sutureless AVR is the best option for redo-operation in older patients with a high surgical risk because it allows for easy rapid deployment implantation, avoids anchoring sutures on a fragile aortic anulus, and reduces cardiopulmonary and aortic cross-clamp times.
View Article and Find Full Text PDFAdaptation of Aortic Bioprosthetic Valves for Pulmonary Position: Comparative Analysis of Transcatheter and Surgical Valves.
J Cardiovasc Transl Res
December 2024
Department of Mechanical and Materials Engineering, University of Denver, 2155 E. Wesley Ave, Room 439, Denver, CO, 80208, USA.
Article Synopsis
- Pulmonary valve dysfunction is frequent in congenital heart disease, often requiring procedures like right ventricular outflow tract reconstruction, with transcatheter pulmonary valve replacement (TPVR) now being a successful alternative to traditional surgery.
- This study compares two bioprosthetic valves: the Carpentier Edwards Perimount Magna Ease surgical valve and the Edwards SAPIEN 3 transcatheter valve, noting that the latter was originally designed for aortic use but has been adapted for pulmonary applications.
- Significant differences were observed in the hydrodynamic and structural characteristics of the valves under pulmonary and aortic conditions, enhancing the understanding of the biomechanics involved in both surgical and transcatheter replacements.
Comparative study of quality of life after aortic valve replacement through partial upper ministernotomy versus full median sternotomy.
Adv Clin Exp Med
October 2024
First Department of Cardiac Surgery and Transplantology, Chair of Cardiac and Thoracic Surgery, Poznan University of Medical Sciences, Poland.
Background: Upper ministernotomy for sutureless aortic prosthesis implantation provides an attractive opportunity compared to conventional access. Although in the last decade, the former has gained popularity, data comparing quality of life (QoL) following these procedures are scarce.
Objectives: The purpose of this study was to assess the patient's QoL after aortic valve replacement (AVR) using a ministernotomy approach compared to a full sternotomy.
Comparison of four aortic bioprostheses: Hancock II St Jude Trifecta Carpentier-Edwards Perimount Magna Magna Ease-mid-term results (COMPARE SAVR study).
J Thorac Dis
August 2024
CAROL-Cardiothoracic Anatomy Research Operative Lab, Department of Cardiovascular Surgery and Transplantology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland.
Background: In the era of percutaneous aortic valve implantation, biological valves are the preferred prostheses implanted in patients undergoing surgical aortic valve replacement (sAVR). The aim was to present a real-life analysis of mid-term sAVR outcomes for the four aortic bioprostheses: the Hancock II, the Carpentier-Edwards Perimount Magna, the Carpentier-Edwards Perimount Magna Ease and the Trifecta valve.
Methods: This is a retrospective study based on data from the Polish National Cardiac Surgery Database.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!